Bedrijfsoverzicht
Immunic, Inc. is a biotechnology entity focused on developing a pipeline of selective oral immunology therapies designed to treat chronic inflammatory and autoimmune diseases within the United States and Germany markets. The company operates within the broader Healthcare sector, specifically targeting the specialized Biotechnology industry, which typically involves high-risk, long-term research and development cycles before potential commercialization. As of the latest data, the enterprise holds a market capitalization of $152.64M and employs a workforce of 92 individuals. These valuation metrics combined with the absence of reported annual revenue indicate that the company remains in a pre-commercialization or early-stage development phase, where value is derived primarily from intellectual property and clinical trial progress rather than current cash flow generation. The lead development program, IMU-838, is currently advancing through Phase 3 clinical and Phase 2 clinical development, highlighting the company's strategic reliance on successful clinical outcomes to drive future revenue streams.
Financiële gezondheid
The financial statements for Immunic, Inc. reflect the typical characteristics of a pre-revenue biotechnology firm, with reported Revenue (TTM) listed as N/A and a Net Income (TTM) of $-97,172,000. The EBITDA stands at $-103,060,000, and the significant gap between the nominal revenue of N/A and the substantial net loss of nearly $97 million reveals a cost structure dominated by extensive research and development expenses rather than sales-related overhead. The company generated Free Cash Flow of $-50,656,500, indicating a net outflow of cash that necessitates a reliance on external capital sources to maintain operations and fund clinical trials. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, which mathematically reflects the absence of revenue and confirms that the company has not yet achieved a commercial sales base to generate traditional profitability margins. On the balance sheet, the company holds Cash of $15.48M against a Debt position of $577,000, creating a net cash position that suggests a conservative leverage profile despite the negative equity implied by other metrics. The Debt to Equity ratio is listed as N/A, likely due to the company's negative shareholders' equity, but the absolute debt level is minimal relative to cash reserves. Liquidity is assessed via a Current Ratio of 0.75, which indicates that current assets are insufficient to cover current liabilities without relying on external financing or asset liquidation. Return on Equity is reported at -1653.1% and Return on Assets at -198.8%, metrics that mathematically demonstrate the dilutive impact of accumulated losses on the book value of the company's equity and assets.
Waarderingsbeoordeling
Valuation multiples for Immunic, Inc. present a complex picture due to the lack of earnings, with a P/E Ratio (TTM) of N/A and a Forward P/E of -3.37. The negative forward P/E implies that the market is pricing the stock based on projected losses rather than current or future profitability, suggesting a valuation model focused on potential asset value or pipeline potential rather than earnings yield. The Price to Book ratio is -21.27, a figure that indicates the market capitalization is significantly detached from the company's tangible book value, a common occurrence for biotechnology firms with intangible assets like drug candidates that are not fully captured on the balance sheet. Since Revenue is N/A, the Price to Sales ratio is also N/A, and the EV/EBITDA stands at -1.34, which serves as an alternative valuation metric showing that the enterprise value is negative relative to earnings before interest, taxes, depreciation, and amortization. The stock's trading range over the past year spans from a 52-Week Low of $0.51 to a 52-Week High of $1.51, providing a volatility band for price analysis. Without a specific current price provided in the source data, the relative position within this $1.00 range cannot be precisely calculated, but the spread between the high and low represents a 196% fluctuation, highlighting significant price instability. The Beta is 1.37, indicating that the stock's price volatility is 37% higher than the broader market, which suggests that Immunic, Inc. carries elevated systematic risk for investors seeking exposure to the biotechnology sector.
Growth & Income
Growth metrics for Immunic, Inc. show Revenue Growth (YoY) as N/A and Earnings Growth (YoY) as N/A, reflecting the company's status as a pre-revenue entity with no historical sales data to calculate year-over-year percentage changes. Because revenue is currently N/A, earnings cannot grow faster or slower than revenue in a traditional sense, as the company is operating in a phase where clinical development costs are the primary expenditure rather than sales growth. The company does not pay a dividend, evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%, meaning that all available cash flow is retained within the business to fund operations and development programs. Consequently, Immunic, Inc. follows a growth-focused strategy typical of biotechnology startups, where earnings are reinvested entirely into the research and development pipeline rather than distributed to shareholders. The overall growth and income profile is defined by the absence of current income generation and reliance on future clinical success to unlock value, with no immediate income return to investors in the form of dividends or capital appreciation from earnings retention.